NEW ORLEANS — In this Healio Video Perspective from the ARVO meeting, Marion R. Munk, MD, PhD, discusses the 24-month analysis from the LIGHTSITE III study.
The study evaluated multiwavelength photobiomodulation (PBM) with the LumiThera Valeda light delivery system in 100 patients with dry age-related macular degeneration. Eyes treated with PBM had a visual acuity improvement of 5.4 letters at month 13. More than 60% of the eyes had a gain of more than five letters after 2 years.
“Photobiomodulation seems to be a very promising tool for the treatment of intermediate AMD,” Munk